NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 09 10:42AM ET
0.0675
Dollar change
-0.0050
Percentage change
-6.90
%
Index- P/E- EPS (ttm)-1.29 Insider Own11.32% Shs Outstand42.20M Perf Week-8.67%
Market Cap2.85M Forward P/E- EPS next Y-1.23 Insider Trans0.00% Shs Float25.00M Perf Month-77.14%
Income- PEG- EPS next Q-0.26 Inst Own43.08% Short Float2.05% Perf Quarter-83.38%
Sales4.91M P/S0.58 EPS this Y34.30% Inst Trans- Short Ratio0.35 Perf Half Y-87.51%
Book/sh0.68 P/B0.10 EPS next Y-44.54% ROA- Short Interest0.51M Perf Year-91.56%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.06 - 0.87 Perf YTD-83.94%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-92.25% Beta2.49
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low18.33% ATR (14)0.02
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM-1.76% Oper. Margin- RSI (14)20.27 Volatility15.64% 18.67%
Employees21 Debt/Eq- Sales Y/Y TTM-51.32% Profit Margin- Recom3.00 Target Price-
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.10 Prev Close0.07
Sales Surprise-21.02% EPS Surprise-171.43% Sales Q/Q-75.90% EarningsMar 12 Avg Volume1.45M Price0.07
SMA20-43.22% SMA50-72.06% SMA200-83.26% Trades Volume44,565 Change-6.90%
Date Action Analyst Rating Change Price Target Change
Dec-11-24Downgrade Oppenheimer Outperform → Perform
Dec-11-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-14-24Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $2
Mar-14-24Downgrade Leerink Partners Outperform → Market Perform $9 → $2
Mar-14-24Downgrade Ladenburg Thalmann Buy → Neutral
Mar-14-24Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24Downgrade Guggenheim Buy → Neutral
Feb-21-24Initiated Guggenheim Buy $10
Dec-17-21Initiated Oppenheimer Outperform $15
Dec-10-21Initiated The Benchmark Company Speculative Buy $7
May-06-25 04:01PM
Apr-15-25 05:27PM
07:00AM
Mar-20-25 09:25AM
Dec-13-24 12:00PM
08:21AM Loading…
Dec-11-24 08:21AM
Dec-10-24 04:01PM
Nov-12-24 10:59PM
Nov-11-24 09:10AM
08:00AM
Oct-28-24 04:01PM
Sep-03-24 04:01PM
Aug-12-24 05:10PM
04:01PM
Jun-24-24 04:12AM
08:00AM Loading…
Jun-06-24 08:00AM
Jun-04-24 07:02AM
07:00AM
Jun-03-24 07:00AM
May-23-24 04:05PM
May-22-24 04:14PM
May-13-24 08:55PM
05:10PM
04:01PM
May-01-24 04:05PM
Apr-30-24 04:05PM
Apr-22-24 04:05PM
Mar-27-24 12:00PM
Mar-21-24 10:20AM
Mar-14-24 08:28AM
05:33PM Loading…
Mar-13-24 05:33PM
04:08PM
04:01PM
Jan-30-24 04:05PM
Jan-22-24 08:00AM
Jan-05-24 08:00AM
Jan-04-24 08:00AM
Nov-13-23 04:05PM
Nov-02-23 04:05PM
Oct-18-23 08:00AM
Aug-28-23 04:00PM
Aug-14-23 04:00PM
Jul-24-23 12:00PM
Jun-12-23 04:00PM
May-25-23 08:00AM
May-24-23 04:05PM
May-22-23 09:30AM
May-16-23 06:18AM
May-15-23 08:00AM
May-04-23 04:05PM
May-02-23 04:05PM
Mar-31-23 12:00PM
Mar-16-23 04:00PM
Feb-28-23 04:05PM
Feb-23-23 10:43AM
Feb-10-23 08:00AM
Feb-09-23 08:00AM
Feb-01-23 04:05PM
Jan-31-23 09:55AM
Jan-09-23 08:05AM
Jan-06-23 05:54PM
06:16AM
Jan-05-23 04:00PM
Nov-16-22 01:13PM
Nov-10-22 04:01PM
Oct-26-22 04:05PM
Aug-30-22 04:05PM
Aug-10-22 04:05PM
Jun-01-22 04:01PM
May-31-22 08:00AM
May-11-22 04:01PM
May-03-22 04:05PM
Apr-11-22 08:00AM
Mar-14-22 04:05PM
04:01PM
Mar-01-22 04:05PM
Feb-03-22 04:05PM
Jan-24-22 08:00AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-31-21 01:50PM
Dec-17-21 07:27AM
07:16AM
Dec-14-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
04:01PM
Sep-29-21 01:06PM
Sep-07-21 04:05PM
Aug-25-21 09:00AM
Aug-11-21 08:55AM
Aug-10-21 04:05PM
11:59AM
Jul-23-21 10:14AM
Jul-07-21 11:38AM
Jun-24-21 08:07AM
Jun-21-21 08:03AM
May-24-21 08:01AM
May-13-21 04:05PM
May-12-21 04:05PM
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Charlton Ralph William IIICHIEF MEDICAL OFFICERDec 16 '24Option Exercise0.0058,3500172,668Dec 20 08:30 PM
Charlton Ralph William IIICHIEF MEDICAL OFFICERDec 10 '24Option Exercise0.00106,4000161,773Dec 20 08:30 PM
Gharib Samir M.PRESIDENT AND CFODec 16 '24Option Exercise0.0075,7500363,841Dec 20 08:28 PM
Gharib Samir M.PRESIDENT AND CFODec 10 '24Option Exercise0.00154,0000356,776Dec 20 08:28 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 16 '24Option Exercise0.00200,7000506,796Dec 20 08:28 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 10 '24Option Exercise0.00358,8000466,121Dec 20 08:28 PM